Artia Global Partners as of Sept. 30, 2024
Portfolio Holdings for Artia Global Partners
Artia Global Partners holds 44 positions in its portfolio as reported in the September 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Eli Lilly & Co. (LLY) | 26.0 | $95M | 108k | 885.94 | |
| Novo-nordisk A S Adr (NVO) | 24.1 | $88M | 742k | 119.07 | |
| Viking Therapeutics (VKTX) | 9.2 | $34M | 533k | 63.31 | |
| Intra Cellular Therapies (ITCI) | 4.3 | $16M | 217k | 73.17 | |
| Astrazeneca Sponsored Adr (AZN) | 4.1 | $15M | 191k | 77.91 | |
| Soleno Therapeutics (SLNO) | 3.8 | $14M | 274k | 50.49 | |
| Alnylam Pharmaceuticals (ALNY) | 2.6 | $9.6M | 35k | 275.03 | |
| Vertex Pharmaceuticals Incorporated (VRTX) | 2.4 | $8.8M | 19k | 465.08 | |
| Vaxcyte (PCVX) | 2.4 | $8.7M | 76k | 114.27 | |
| Argenx Se Sponsored Adr (ARGX) | 2.2 | $8.2M | 15k | 542.08 | |
| Axsome Therapeutics (AXSM) | 2.2 | $7.9M | 88k | 89.87 | |
| Protagonist Therapeutics (PTGX) | 1.5 | $5.6M | 124k | 45.00 | |
| Neurocrine Biosciences (NBIX) | 1.4 | $5.2M | 45k | 115.22 | |
| Revolution Medicines (RVMD) | 1.2 | $4.3M | 96k | 45.35 | |
| Dyne Therapeutics (DYN) | 1.2 | $4.3M | 120k | 35.92 | |
| Verona Pharma Sponsored Ads (VRNA) | 1.2 | $4.3M | 149k | 28.77 | |
| Merus N V (MRUS) | 1.1 | $4.0M | 80k | 49.96 | |
| Insmed Com Par $.01 (INSM) | 1.1 | $3.9M | 53k | 73.00 | |
| Celldex Therapeutics Com New (CLDX) | 0.7 | $2.6M | 75k | 33.99 | |
| Crinetics Pharmaceuticals In (CRNX) | 0.6 | $2.3M | 46k | 51.10 | |
| Ideaya Biosciences (IDYA) | 0.5 | $2.0M | 63k | 31.68 | |
| Mereo Biopharma Group Spon Ads (MREO) | 0.5 | $1.7M | 421k | 4.11 | |
| Springworks Therapeutics (SWTX) | 0.5 | $1.7M | 54k | 32.04 | |
| Nuvalent Inc-a (NUVL) | 0.4 | $1.6M | 15k | 102.30 | |
| Xenon Pharmaceuticals (XENE) | 0.4 | $1.6M | 40k | 39.37 | |
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 0.4 | $1.3M | 80k | 15.99 | |
| Eyepoint Pharmaceuticals Com New (EYPT) | 0.3 | $1.2M | 156k | 7.99 | |
| Charles River Laboratories (CRL) | 0.3 | $1.2M | 6.3k | 196.97 | |
| Ionis Pharmaceuticals (IONS) | 0.3 | $1.2M | 31k | 40.06 | |
| Keros Therapeutics (KROS) | 0.3 | $1.2M | 20k | 58.07 | |
| Kura Oncology (KURA) | 0.3 | $1.1M | 57k | 19.54 | |
| Ascendis Pharma A/s Sponsored Adr (ASND) | 0.3 | $1.1M | 7.4k | 149.31 | |
| Annexon (ANNX) | 0.3 | $1.0M | 172k | 5.92 | |
| Corbus Pharmaceuticals Hldgs Com New (CRBP) | 0.3 | $978k | 47k | 20.63 | |
| Silence Therapeutics Ads (SLN) | 0.3 | $954k | 53k | 18.18 | |
| Syndax Pharmaceuticals (SNDX) | 0.3 | $929k | 48k | 19.25 | |
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 0.2 | $901k | 54k | 16.60 | |
| Alector (ALEC) | 0.2 | $901k | 193k | 4.66 | |
| Disc Medicine (IRON) | 0.2 | $660k | 13k | 49.14 | |
| Larimar Therapeutics (LRMR) | 0.2 | $593k | 91k | 6.55 | |
| Acelyrin (SLRN) | 0.1 | $459k | 93k | 4.93 | |
| Madrigal Pharmaceuticals (MDGL) | 0.1 | $330k | 1.6k | 212.22 | |
| Summit Therapeutics (SMMT) | 0.1 | $318k | 15k | 21.90 | |
| Q32 Bio (QTTB) | 0.1 | $210k | 4.7k | 44.62 |
